Nivolumab plus ipilimumab

Malignant pleural mesothelioma is an aggressive cancer with limited therapeutic options. Pemetrexed plus platinum is often the first treatment option that clinicians turn to. There are now several options for second treatment therapy. This is useful in patients with relapsed mesothelioma. Yet some of these treatment therapies remain controversial. Several drugs were recently introduced to treat relapsed mesothelioma. A new study conducted a meta-analysis to check the efficacy of these drugs. After Chemotherapy, What Comes Next? Nivolumab alone or nivolumab plus ipilimumab provided significantly longer patient survival. In fact, treatment with nivolumab plus ipilimumab was found to have the best survival rates. Other treatments had a good survival rate compared with a placebo. These other treatments included tremelimumab, vorinostat, and chemotherapy…